Back to Search
Start Over
Pristimerin suppresses colorectal cancer through inhibiting inflammatory responses and Wnt/β-catenin signaling.
- Source :
-
Toxicology & Applied Pharmacology . Jan2020, Vol. 386, pN.PAG-N.PAG. 1p. - Publication Year :
- 2020
-
Abstract
- Pristimerin, a triterpenoid, has exhibited potential anti-inflammatory and anti-tumor activities. Nevertheless, the role and mechanism of pristimerin in intestinal inflammation and colon cancer require further investigation. Here, we found that pristimerin protected mice from dextran sulfate sodium (DSS)-induced colitis, restoring epithelial damage and reducing tissue inflammation and inflammatory cell infiltration. In addition, pristimerin dramatically reduced the number and size of the tumors in a azoxymethane (AOM)/DSS-induced colitis-associated colorectal cancer (CAC) model. Furthermore, we found that pristimerin suppressed Wnt/β-catenin signaling by RNA-Seq. Pristimerin inhibited Wnt/β-catenin signaling via activation of GSK3β, thereby suppressing Wnt target gene expression in colon cancer HCT116 and HT-29 cells. In HCT116 colon cancer xenografts and APC min/+ mice, which undergo spontaneous intestinal tumorigenesis, administration of pristimerin reduced the tumor progression and decreased the expression of phosphorylated GSK3β Ser 9, β-catenin, cyclin D1 and c-Myc. These results suggest that pristimerin is a potent agent for preventing colon inflammation and carcinogenesis. • Pristimerin ameliorates DSS-induced colitis in mice. • Pristimerin inhibits colitis-associated colorectal cancer. • Pristimerin disrupts the progression of spontaneous intestinal tumorigenesis. • Pristimerin suppresses Wnt/β-catenin via activation of GSK3β. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0041008X
- Volume :
- 386
- Database :
- Academic Search Index
- Journal :
- Toxicology & Applied Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 140316085
- Full Text :
- https://doi.org/10.1016/j.taap.2019.114813